Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine +/- Naltrexone in TRD
NCT02911597Phase 1Completed
- Sponsor
- Stanford University
- Start
- Sep 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by Stanford University. Primary endpoint: Hamilton Rating Scale for Depression. Started Sep 2016; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02911597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911597.